One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Fortress Biotech, Inc.
FBIO · NCM · Healthcare · Biotechnology
Current price
$1.91
52-week range
$1.79 - $4.53
Market cap
$63.70M
Balance sheet
Healthy
-8.06x Concerning
Net cash $143.26M. Interest coverage shows how many times profit covers the interest bill.
What stands out
2 Rewards
0 Risks
2 rewards · 0 risks
View details ↓What this company does
Fortress Biotech, Inc.
Fortress Biotech develops medicines for various health conditions, from acne and rosacea to more serious diseases like cancer and rare genetic disorders. Their main income will eventually come from selling these approved drugs, which matters because it's how they fund further research and development for new treatments.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-20.06M
FY2024 Q4
$-12.91M
FY2025 Q2
$-27.56M
FY2026 Q2
$-59.36M
Revenue
$18.72M
Net income
$-468.00K
Diluted EPS
-0.08
Operating cash flow
$-59.28M
Free cash flow
$-59.36M
Fetching…
Sources
Revenue
$16.04M
Net income
$110.37M
Diluted EPS
2.82
Operating cash flow
$203.85M
Free cash flow
—
Fetching…
Sources
Revenue
$16.08M
Net income
$-3.94M
Diluted EPS
-0.15
Operating cash flow
$-12.54M
Free cash flow
—
Fetching…
Sources
Revenue
$17.63M
Net income
$5.85M
Diluted EPS
0.11
Operating cash flow
$-6.11M
Free cash flow
—
Fetching…
Sources
Revenue
$16.41M
Net income
$15.49M
Diluted EPS
0.45
Operating cash flow
$-27.56M
Free cash flow
$-27.56M
Fetching…
Sources
Revenue
$13.14M
Net income
$-10.58M
Diluted EPS
-0.48
Operating cash flow
$-19.56M
Free cash flow
—
Fetching…
Sources
Revenue
$15.12M
Net income
$-6.76M
Diluted EPS
-0.16
Operating cash flow
$-12.91M
Free cash flow
$-12.91M
Fetching…
Sources
Revenue
$14.63M
Net income
$-12.87M
Diluted EPS
-0.76
Operating cash flow
$-20.06M
Free cash flow
$-20.06M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.91
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $143.3M - more cash than debt. Interest coverage -8.1x.
Net debt
$-143.26M
Interest coverage
-8.06x
Fortress Biotech, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
FBIO
BASELINE
Fortress Biotech, Inc.
Total debt $53.32M Interest coverage -8.06x This is the baseline the peer rows are being compared against.
Total debt $7.61M Interest coverage -1,991.57x Neither company has much profit cushion over interest right now.
Total debt $46.16K Interest coverage -9.17x Neither company has much profit cushion over interest right now.
Total debt $162.18M Interest coverage -0.54x Neither company has much profit cushion over interest right now.
Total debt $7.50M Interest coverage -25.11x Neither company has much profit cushion over interest right now.
What you should know
The case for and against FBIO
2 Rewards
0 Risks
Rewards
-
Revenue grew 8.2% last year.
-
Returns 116.0% on equity, ahead of 80% of its peers.
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
0.69x
Forward P/E
-1.09x
P/B
0.39x
P/S
0.93x
EV/EBITDA
1.51x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
63.3%
Operating margin
-53.5%
Net margin
163.3%
ROE
116.0%
ROA
-7.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.26x
Current ratio
3.96x
Quick ratio
3.76x
Total debt
$53.32M
Total cash
$196.58M
Growth
How the business has been compounding
Revenue TTM
$68.47M
Revenue 5Y CAGR
-2.1%
EPS TTM
2.76
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$125.92M
Free CF TTM
$-80.19M
FCF margin
-117.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—